AIM
NKTR icon

AIA Investment Management’s Nektar Therapeutics NKTR Stock Holding History

AIA Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-20
Closed -$5K – 382
2019
Q3 		$5K Buy
+20
New +$7.33K 0.01% 358

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

AIA Investment Management's NKTR Position: Q4 2019 in Review

AIA Investment Management sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 20 shares — an estimated $5K sold.

AIA Investment Management first reported a position in NKTR in Q3 2019 and held it in 1 quarter. The position peaked at $5K in Q3 2019. 281 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

  • AIA Investment Management reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
  • AIA Investment Management sold 20 Nektar Therapeutics shares in Q4 2019, an estimated $5K.
  • AIA Investment Management first reported a position in Nektar Therapeutics in Q3 2019 and held it in 1 quarter.
  • AIA Investment Management's Nektar Therapeutics position peaked at $5K in Q3 2019.
  • 281 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on AIA Investment Management's 13F filing for Q4 2019, filed 12 Feb 2020.